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Efl'ects of TNFa and verocytotoxin cytotoxicity in human glomerular
microvascular endothelial cells. In the pathogenesis of the hemolytic
uremic syndrome (HUS), endothelial damage of glomeruli and arterioles
of the kidney appears to play a central role. Previous studies have shown
that verocytotoxin-i (VT-i) cytotoxicity on human vein endothelial cells
require additional stimuli, in particular the inflammatory mediator tumor
necrosis factor alpha (TNFa). In this study the effects of VT on human
glomerular microvascular endothelial cells (GMVEC) were examined. A
reproducible method was developed for the isolation and purification of
large numbers of highly purified GMVEC. The obtained GMVEC were
over 99% pure; their endothelial origin was demonstrated by the expres-
sion of the endothelial antigens von Willebrand factor, EN-4, PECAM-I
and V,E-cadherin. Upon stimulation with TNFs the cells expressed the
endothelial-specific adhesion molecule E-selectin. A limited number of
fenestral structures was observed by scanning electron microscopy (SEM),
suggesting glomerular origin of the endothelial cells. Cytotoxicity of VT-I
to GMVEC was evaluated by determination of the number of viable
adherent cells and by assay of overall protein synthesis after exposure to
varying concentrations of VT-i. In non-stimulated GMVEC, cytotoxicity
of VT-i was inversely related to the degree and duration of confluence,
subconfluent cells being the most sensitive. In highly confluent GMVEC,
VT cytotoxicity required pre-exposure of the cells to the inflammatory
mediator TNFa, which induced an increase in the number of VT receptors
on GMVEC. Thin layer chromatography of extracted glycolipids from the
GMVEC showed binding of VT-i to globotriaosylceramide (Gb3), known
to be the functional receptor for VT. There were no major differences in
protein synthesis inhibition with equal concentrations VT-I and VT-2. In
conclusion, in this study we provide a reproducible method to isolate,
purify and culture well characterized human GMVEC on a routine basis.
In vitro studies with these GMVEC demonstrate that VT cytotoxicity
depends on the degree of confluence and the additional preexposure to
the inflammatory mediator TNFa. These observations provide further
insight into the complex events that may occur in glomeruli in the
pathogenesis of HUS.
The hemolytic uremic syndrome (HUS) is characterized by
renal failure, thrombocytopenia and hemolytic anemia [I]. Endo-
thelial damage of glomeruli and kidney arterioles appears to play
a pivotal role in the pathogenesis of HUS. Histopathological
studies of the kidney in HUS patients reveal swollen and detached
endothelial cells and deposits of fibrin, all within the glomerulus
[21. In severe cases of HUS endothelial cell damage is not limited
to the kidney, but extends to other organs, such as brain and
pancreas. Infection with a verocytotoxin (VT) producing E. coli
has been implicated in the etiology of the epidemic form of HUS
[31. In vitro studies with umbilical vein and adult vein endothelial
cells indicate that endothelial cells become more susceptible to
VT if prestimulated with inflammatory mediators [4—7]. Induction
of the globotriaosylceramide (Gb3) receptor, known to be the
functional receptor for VT, proved to be the mechanism by which
inflammatory mediators induce increased susceptibility to VT [6].
A number of observations have indicated morphological, bio-
chemical and functional heterogeneity between macro- and ml-
crovessel endothelial cells, and even between microvascular en-
dothelial cells derived from different organs [8]. Therefore, to test
if non-stimulated glomerular microvascular endothelial cells
(GMVEC) are more susceptible to verocytotoxin-1 (VT-I) than
their venous counterparts, it would be desirable to directly study
GMVEC. The isolation and culture of human renal [9] and
glomerular [10—12] MVEC has been reported, but currently no
procedure is available to culture human GMVEC on a routine
basis. Here, we report on a reproducible method to isolate, purify
and culture large numbers of GMVEC that are free of contami-
nating cells, and on the characterization of these cells. Further-
more, we describe the effects of TNFcr and the degree of
confluence on VT cytotoxicity for human GMVEC. We found
that VT-I cytotoxicity for highly confluent GMVEC requires
pre-exposure of the cells to the inflammatory mediator TNFa,
which is similar to previous findings on umbilical and adult vein
endothelial cells [4—7]. These data seem to contrast to observa-
tions by Obrig et al [13], who showed that VT-i had an identical
toxic effect on TNFa-stimulated and non-stimulated renal
MVEC. To explain these apparent differences, we analyzed the
effects of VT-i on GMVEC during maintenance in a confluent
culture, and demonstrate that the sensitivity of GMVEC for VT-i
is markedly reduced in the post-confluent state.
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Isolation of glomeruli
Studies were performed with human kidneys not suitable for
transplantation because of anatomical anomalies, technical or
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immunological reasons. Written consent was obtained from the
Medical Ethical Review Board of the University Hospital Nijme-
gen, The Netherlands. In general, the procedure was started as
soon as possible after explantation of the kidney, usually within 24
to 72 hours. Glomeruli were isolated under sterile conditions by
dissecting the cortex followed by a gradual sieving procedure
(sieves with opening sizes 2000 jxm to 53 jim; Endecotts, London,
UK). Depending on the age of the donor, the glomeruli were
collected on top of the screens with opening sizes of 180, 125, 108,
90 or 53 jim and digested with 0.1% (wt/vol) collagenase type 2
CLS (Worthington, NJ, USA) in M199 (Biowithaker, MD, USA)
for two hours at 37°C. Following digestion glomerular remnants
were shaken vigorously to loosen up the glomeruli and liberate the
endothelial cells. Subsequently the glomerular remnants were
washed, centrifuged and resuspended in complete media that
consisted of M199 supplemented with 10% (vol/vol) newborn calf
serum (NBCS; GIBCO, Grand Island, NY, USA), 10% (vol/vol)
human serum (HS; local blood bank), 2 mmol/liter glutamine
(ICN Biomedicals, Zoetermeer, The Netherlands), 100 IU/ml
penicillin/0.1 mg/mi streptomycin and 5 U/ml heparin (Leo Phar-
maceuticals, Weesp, The Netherlands) and 150 mg/liter crude
preparation of endothelial cell growth factor (prepared from
bovine brains as described by Maciag et al [141) and plated on
gelatin (1%; Fluka BioChemika, Buchs, Switzerland) coated wells
(Costar Corp., Cambridge, MA, USA).
Primary culture and purification
In general the glomerular remnants attached within one to two
days, after which outgrowth of predominantly cells of epithelial
and endothelial origin was noted. Daily monitoring of proliferat-
ing cells determined the exact timing of separating the endothelial
and epithelial cells, usually within three to eight days after plating
of the glomerular remnants. The purification procedure consisted
basically of three steps. First, selective trypsinization was per-
formed, allowing endothelial cells to detach and leaving the
epithelial cells attached to the plate. Selectivity in cell detachment
was reached by incubating the cells with trypsin/EDTA (0.5 g
trypsin 1:250/0.2 g EDTA in 1 liter of Modified Puck's Saline A;
Gibco) at room temperature for a short incubation period, the
duration of which was determined during visual inspection of the
cell layer by phase-contrast microscopy (about 60 seconds). Sec-
ond, to relieve glomerular remnants, which proved to be a source
of contaminating cells when subcultured, trypsinized cells and
glomerular remnants were filtrated through a 38 jim sieve. The
filtrate was collected, washed and pelleted by centrifugation
(200 X g). Third, the pellet was resuspended in Hanks' balanced
salts (ICN Biomedicals)/10% (vol/vol) fetal calf serum (FCS;
GIBCO) and incubated with a monoclonal antibody against
PECAM-1 (CLB, Amsterdam, The Netherlands) for 30 minutes
on ice. Excess of unbound anti-PECAM-1 monoclonal was re-
moved by washing for three times. Subsequently, an immunomag-
netic separation technique with dynabeads coated goat anti-
mouse antibodies (Dynal A.S; Oslo, Norway) and a magnetic
particle collector (Dynal A.S) was performed to selectively collect
glomerular endothelial cells. In general the number of beads used
was calculated according to the following formula: (total number
of cells) X (% estimated endothelial cells) X 3. The use of too
many beads per cell reduced the attachment of the endothelial
cells. PECAM-1 positive cells were plated on gelatin-coated wells
and maintained at 37°C with 5% CO2 atmosphere. The medium
was changed every two to three days and cells were passaged with
trypsin/EDTA onto gelatin-coated wells at a split ratio of 1:2 or
1:3. In general it was necessary to repeat the immunomagnetic
separation technique once or twice or to perform additional
manual weeding to obtain pure cultures of GMVEC.
In case the epithelial cells seemed to overgrow the endothelial
cells in the primary culture from morphological point of view, the
protocol as described above was preceded by a negative immuno-
magnetic separation technique using an epithelial-cell specific
antibody (CD 26; Pharmingen, San Diego, CA, USA) to remove
the contaminating epithelial cells.
Characterization
Primary and serially passaged cultures were characterized using
three criteria.
(1.) Morphological criteria. Outgrowth from collagenase treated
glomerular remnants and subcultures were examined with a
phase-contrast microscope. Photomicrographs were made at var-
ious passages using Technical Pan films.
(2.) Immunological criteria. The presence of endothelial cell-
specific antigens was determined by performing indirect immuno-
fluorescence studies with a panel of endothelial cell-specific
monoclonal antibodies (MoAb). GMVEC were seeded on gela-
tin-coated glass-coverslips and grown until confluence. Cells were
fixed in 80% (vol/vol) aceton for 10 minutes at 4°C and rinsed with
phosphate-buffered saline (PBS). The presence of von Willebrand
factor was demonstrated by indirect immunofluorescence staining
with rabbit anti-human von Willebrand antiserum [1:80 dilution in
10% (vol/vol) pig serum; DAKO; Glostrup, Denmarki and FITC-
swine anti-rabbit Ig (1:20 in PBS; DAKO). The presence of other
endothelial-cell specific antigens such as PECAM-1, EN-4 antigen
and V,E-cadherin was investigated by incubating the fixed cells
with anti-PECAM-1 MoAb (10 jig/mI; CLB, Amsterdam, The
Netherlands), MoAb EN-4 [15] (10 jig/mi; Sanbio, Uden, The
Netherlands) and anti-V,E-cadherin MoAb [16] (1:500; provided
by Dr. Dejana, Mario Negri Institute, Milan, Italy) in PBS/10%
goat serum. After a 30-minute incubation period at room temper-
ature the cells were washed twice with PBS and incubated with
FITC-goat anti-mouse Ig (1:20; DAKO). After a 30-minute
incubation time at room temperature, cells were washed twice
with PBS and mounted with Vectashield (Burlingame, CA, USA)
under a coverslip and investigated using a fluorescence micro-
scope. Similar immunofluorescent assays were carried out using
MoAb to control for contamination with mesangial-cells (anti-a-
smooth muscle actin, clone 1A4; Sigma, Zwijndrecht, The Neth-
erlands) and epithelial cells (monoclonal anti-cytokeratin 8, M20;
provided by Dr. G. van Muijen, University Hospital Nijmegen,
The Netherlands [17]). The expression of the endothelial-cell
specific adhesion molecule E-selectin upon stimulation with
TNFa was determined by ceil-ELISA. GMVEC were grown until
confluence in 96-well tissue culture plastic plates (Costar Corp.)
and subsequently exposed to TNFa (10 ng/ml) during a four-hour
incubation period. Cells were rinsed once with M199 and fixed in
0.025% glutaraldehyde. Following fixation wells were incubated
with MoAb against E-selectin (ENA-2; gift of Dr. J. Leeuwen-
berg, University Hospital Maastricht, The Netherlands [18])
diluted in M199/5% FCS at a concentration of 10 jig/mI during 60
minutes at 37°C. The cells were washed twice with PBS/Tween
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and incubated with peroxidase labeled, goat anti-mouse second
antibody (1:1000; DAKO) for 30 minutes at 37°C. After washes
with PBS/Tween o-phenylenediamine-peroxide was added. The
reaction was stopped by the addition of 2.5 mol/liter H2S04 (50
x1/well). Absorbency was read at 492 nm on a Titretek Multiscan.
Absorbency with second antibody alone was subtracted from all
absorbency values expressed. Expression of E-selectin was also
analyzed by performing immunofluorescence studies and FACS
analysis as described above with minor adjustments, in that the
cells were incubated with the primaly and secondary antibodies
diluted in PBS plus (PBS plus Mg2 and Ca2) and cells were only
fixed after incubation with primary and secondary antibodies.
(3.) Ultrastructure. Evaluation of human GMVEC by scanning
electron microscopy was performed by the osmium-thiocarbohy--
drazide-osmium technique. GMVEC grown on gelatin coated
glass-coverslips were rinsed with Mi99 and fixed for two hours at
room temperature with 2.5% glutaraldehyde in 0.1 mol/liter
cacodylate buffer. The cells were then rinsed carefully with 0.1
mol/liter cacodylate/6.8% sucrose pH 7.38 and postflxed with 1%
0s04 in the same cacodylate buffer. Subsequently the cells were
rinsed with aquabidest and immersed in 1% filtrated thiocarbo-
hydrazide-solution (TCH). Following immersion, alternate fixa-
tion in 0s04 and immersion in TCH and fixation in 0s04 were
repeated after which the cells were selectively dehydrated in
graded alcohol solutions and critical point dried. Cells were
visualized with a SEM Jeol 1200 EX/2 at an accelerating voltage
of 50 Ky.
Cytotoxicily assay
GMVEC were cultured in complete medium on gelatin coated
24-well plates and grown until confluence. Five days after reaching
confluence (highly confluent) cells were preincubated with or
without TNFa (10 ng/ml) for 24 hours. The next day the medium
was aspirated and new medium with different concentrations of
VT-I and VT-2 (provided by Prof Karmali; Hospital for Sick
Children, Toronto, Canada) was added. VT-i and VT-2 were
diluted in medium with 20% FCS instead of 10% NBCS and 10%
HS, since previous studies have indicated that NBCS and HS may
have neutralizing activity against VT-i and VT-2. After 8 and 24
hours the cells were washed with PBS, released with trypsin/
EDTA and subsequently viable, Trypan blue excluding cells were
counted with a hemocytometer. In order to study the influence of
confluence, cells at different degrees of confluence were preincu-
bated with TNFx and tested for VT-i cytotoxicity as described
above.
lodination of VT-i and the binding of J25j VT-i to human
GMVEC
VT-i was radiolabeled with Na-'251 according to the lodogen
procedure [19]. The radioactive activity of '251-VT-1 ranged from
10 to 12 xCi4tg of protein. GMVEC were grown in 24-well plates
until they reached confluence. After five days the cells were
preincubated with or without inflammatory mediators for 24
hours at 37°C. Subsequently the GMVEC were washed with M199
medium/0.i% human serum albumin (HSA) and incubated for
three hours with 0.25 to 32 nmol/liter 25I-VT-1 in M199 medium/
0.1% HSA at 0°C. After three hours the incubation medium was
aspirated and the cells were washed for five times in Mi99
medium/0.1% HSA. Cell-associated 1251-VT-1 was determined by
solubilizing the cells in 400 jsl 1 mol/liter sodium hydroxide at
room temperature and counting radioactivity in a gamma-
counter. Non-specific binding was assessed in parallel incubation
by determining 1251-VT-I binding in the presence of a 100-fold
excess of unlabeled VT-i. Cellular specific binding was calculated
by subtracting the non-specific binding from the cellular binding
of l25\T as determined in the absence of unlabeled VT-i. All
determinations were done in duplicate. Data were analyzed using
the method described by Scatchard [201. To investigate whether
Gb3 is also the functional receptor for VT in GMVEC, TNFa-
stimulated GMVEC were incubated with a MoAb against Gb3
[21] (MoAb anti-CD77; clone #38-13; Biodesign International,
Kennebunk, ME, USA) one hour before and during assaying the
binding of 1251-VT-1.
Glycolipid extraction and thin layer chromatography (TLC)
Highly confluent GMVEC were cultured in six-well plates (20
cm2) for 24 hours with and without TNFa (10 nglml). Subse-
quently the cells were washed with PBS and trypsinized, after
which glycolipids were extracted and separated by methods earlier
described by Lingwood et al [22]. Following thin layer chroma-
tography, the silica gel TLC plate was incubated with 50 ml, 1.5
nmol/liter 1251-VT-i in 1% BSA and 0.05% Tween-20 in PBS
during four hours at 4°C. The plate was washed extensively with
PBS supplemented with 1% BSA and 0.05% Tween-20, air dried
and analyzed by a Fuji BAS 1000 phosphor-imager.
Protein synthesis
Protein synthesis was determined by assaying the incorporation
of 35S-labeled methionine (0.25 jxCi/ml complete medium) in
35S-proteins during an 8 to 24 hours incubation period with
different concentrations of VT-i and VT-2. After incubation, the
cells were washed and 35S-labeled cellular proteins were precipi-
tated by adding 10% trichloroacetic acid. Precipitated proteins
were dissolved in 0.3 ml 0.3 mol/liter NaOH, 60 sl 1.5 mol/liter
HC1 was added and precipitated radioactivity was counted in a
liquid scintillation counter.
Results
Isolation and punfi cation of human GMVEC
Incubation of pure populations of human glomeruli, which were
isolated by a gradual sieving procedure with collagenase for two
hours at 37°C followed by vigorously shaking, resulted in small
clumps consisting of glomerular remnants. These remnants at-
tached to gelatin-coated plates within one to two days. Following
attachment, outgrowth of primarily endothelial and epithelial cells
was noted (Fig. IA), the latter easily overgrowing the GMVEC.
As judged by phase-contrast microscopy the outgrowing endothe-
hal cells demonstrated a slightly elongated morphology with a
nucleus containing one or two nucleoli and a dark perinuclear
cytoplasm area that was surrounded by a bright halo. Epithelial
cells displayed the epithelial cell specific cobblestone pattern of
densely packed polygonal cells. Besides the tendency of the
contaminating epithelial cells to overgrow the endothelial cells,
these cells seemed to inhibit the growth of endothelial cells,
probably by producing growth inhibiting factor(s). Therefore, it
was crucial to remove epithelial cells and purify the endothelial
cell populations. The purification procedure consisted basically of
three steps: selective detachment of most of the endothelial cells
by trypsin-EDTA treatment; removal of glomerular remnants by
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passages 3 to 4 (Fig. 1C). Subculturing of these GMVEC with of
split ratio of 1:3 or 1:6 has been successfully accomplished to
passage 10 without significant changes in morphology and func-
tion.
Identification and characterization of human GMVEC
Upon examination by phase contrast microscopy, confluent
monolayers of human GMVEC exhibited a typical contact-inhib-
ited morphology (Fig. 1C). They were not contaminated by
spindle shaped and/or overcrossing mesangial cells [23], or by
epithelial cells, which display a vety regular, polygonal cobble-
stone morphology [24]. The endothelial and glomerular nature of
the cells was confirmed by the expression of endothelial-specific
antigens and by their ultrastructure.
Indirect immunofluorescence microscopy revealed the presence
of von Willebrand factor in a distinct granular pattern (Fig. 2A).
Furthermore, the endothelial specific antigens EN-4, PECAM-1
and V,E-cadherin antigen were present at the regions of intercel-
lular contacts (Figs. 2 B, C, E). When the GMVEC were
subcultured for more than 10 passages, the cells remained positive
for all these markers. The cultured human GMVEC showed no
immunoreactivity to the anti-cytokeratin 8 [17] antibody or to the
anti-a smooth-muscle actin antibody, excluding the contaminating
epithelial and mesangial cells, respectively (data not shown).
Upon stimulation with TNFa (10 ng/ml) for four hours, expres-
sion of the endothelial cell specific protein E-selectin was induced
on human GMVEC, whereas unstimulated controls did not
express E-selectin (OD, 3.24 0.55 and OD, 0.15 0.02,
respectively, as determined by cell-ELISA; mean SD; N = 3).
Similar results were obtained when E-selectin expression was
determined by indirect immunofluorescence or FACS analysis
(data not shown).
At the ultrastructural level, the cultured human GMVEC
displayed small pores with a diameter of about 100 nm, as
revealed by scanning electron microscopy (Fig. 3). These struc-
tures were not observed in human umbilical and iliac vein
endothelial cells (data not shown), and probably represent
fenestrae. The persistent presence of these fenestral structures in
GMVEC in Vitro, although to a lesser extent when quantified per
square micrometer in vivo, points not only to the glomerular
endothelial origin, but also to a certain degree of differentiation of
the cultured GMVEC.
Fig. 1. A. Phase-contrast microscopy of primaiy culture of human GMVEC.
Human glomeruli were isolated by a gradual sieving procedure and
vigorously treated with collagenase. Subsequently the glomerular rem-
nants were plated on gelatin coated plates that attached within Ito 2 days.
Following attachment, outgrowth of primarily endothelial (>) and epithe-
hal (*) cells was noted. B. Phase-contrast microscopy of GMVEC in the
first passage after performing the initial purification procedure. Predom-
inantly cells of endothehial origin surrounded by immunomagnetic beads
are visible. C. Phase-contrast microscopy of a confluent monolayer of
purified third passage human GMVEC (magnification X75).
filtration; and selective collection of GMVEC by binding to
anti-PECAM-1 MoAb and immunomagnetic separation tech-
nique (Fig. 1B). The immunomagnetic separation with anti-
PECAM-1 MoAb was repeated once or twice and additional
manual weeding of contaminating cells was performed at passages
2 to 3. This resulted in highly purified cultures of GMVEC by
Effect of VT-I on viabilily of human GMVEC
To evaluate whether GMVEC are sensitive to the toxic effect of
VT-i, cell viability was estimated by counting viable adherent cells
with a hemocytometer after an 8 to 24 hour exposure to various
concentrations of VT-i. VT-I at concentrations ranging from 1
fmol/hiter to 10 nmol/hiter did not significantly affect cell viability
of three different populations of highly confluent human GMVEC
when cultured under basal conditions over a 24-hour time period.
At the highest dose tested, a 24 hour incubation with VT-I (10
nmol/hiter) caused 0%, 1% and 6% cytotoxicity, respectively, in
these three different populations of highly confluent GMVEC.
Similar to previous observations from our group, studying the
effects of VT-i on human umbilical vein and human femoral vein
endothelial cells (HUVEC) [6], human GMVEC cultured and
treated under identical conditions became susceptible to the
cytotoxic effect of VT-i after preincubation with the inflammatory
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Fig. 2. Endothelial-specific markers were visualized by indirect immunofluorescence microscopy as described in the Methods section. A. von Willebrand
factor antigen. B. EN-4 antigen. C. PECAM-1 antigen. D. Negative control lacking primary antibody (showing an immunomagnetic bead). E. V,E
cadherin antigen. The magnification for A to E was 350-fold.
mediator TNFs (10 ng/mI). In TNFa-stimulated GMVEC, VT-i
incubation at 10 nmol/iiter for 24 hours resulted in the three
different populations of GMVEC studied, in respectively 80%,
76% and 90% cytotoxicities.
Figure 4 shows the time and concentration dependent effect of
VT-i during an 8- to 24-hour incubation period on cell-viability of
unstimulated and TNFa-stimulated GMVEC isolated from one
representative donor out of three. The threshold dose to exert a
cytotoxic effect on TNFa-stimulated GMVEC was 0.1 pmol/Iiter.
No cytotoxicity was noticed when VT-i was heat-inactivated (30
mm at 90°C) prior to addition to the culture medium indicating a
specific cytotoxic effect of VT-i.
Susceptibility of the human GMVEC did not only depend on
the additional stimulation with inflammatory mediators but also
on the degree of confluence of the GMVEC. Figure 5 shows the
influence of confluence of a representative population of GM-
VEC on the susceptibility for VT-I. Cell-viability of subconfluent
and confluent GMVEC was affected under basal conditions by
VT-I whereas highly confluent GMVEC were resistant to the
cytotoxic effect of VT-I. Pre-exposure of GMVEC to TNFa had
a marked effect on VT-I cytotoxicity in highly confluent cells,
while it increased VT-I cytotoxicity in subconfluent cells only to a
limited extent. Similar results were obtained with GMVEC of two
other donors (data not shown).
TNFa increases the number of VT-i receptors on human GMVEC
Binding of '251-VT-1 to human GMVEC was saturable (Fig.
6A) and specific; 25I-VT-1 binding was entirely (>95%) dis-
placed by a 100-fold excess of unlabeled VT-i. Pretreatment of
GMVEC with TNFa resulted in an increase in '251-VT-1 binding
(Fig. 6A). Scatchard plot analysis revealed that one type of
binding site is involved in VT-i binding to human GMVEC (Fig.
6B). Furthermore, it showed that 24 hours of preincubation of
human confluent GMVEC with TNFa caused a threefold increase
in the number of specific binding, while the apparent affinity of
VT-I did not change significantly (1.5 nmol/liter and 1.7 nmol/
liter, respectively). In addition to TNFa, interleukin-la and
bacterial lipopolysaccharide induced an increase in specific 1251..
VT-I binding to GMVEC (1.6 0.2-fold and 1.7 0.4-fold
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Fig. 3. Scanning electron microscopy of cultured
human GMJ/EC. Cells were used after six
passages; notice the small pores, approximately
uniform in size and with a diameter of about
100 nm, suggestive for fenestral structures. The
arrow (") indicates a representative fenestral
structure (magnification 15000-fold).
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Fig. 4. Time- and dose-dependent cytotoxicity of VT-I for human GMVEC.
Human GMVEC ofone representative donor (sixth passage) out of three
were grown to confluence and maintained for five days in the confluent
state. Subsequently, the cells were preincubated for 24 hours without
(open symbols) or with TNFa (10 ng/ml; closed symbols) after which the
cells were washed and incubated with either control medium (the same
culture medium without addition; , S) or VT-I (10 nmol/Iiter; A, A),
VT-I (0.1 nmol/l; 0, S) for 8 and 24 hours. After the indicated periods of
time, the number of viable adherent cells was counted with a hemocytom-
eter. Similar results were obtained in two other experiments with two
different donors.
increase, respectively); interleukin-6 (0.9 0.07) and interleu-
kin-4 (0.9 0.02) did not affect VT-i binding to GMVEC.
Characterization of the ligand to which VT-i hinds on
human GMVEC
To investigate whether globotriaosylceramide, which has been
demonstrated to be the receptor for VT-i on endothelial cells
[25], lymphocytes [26] and human kidney [271, is also the receptor
for VT-i on human GMVEC, TNFa-stimulated GMVEC were
incubated with a MoAb against Gb3 one hour before and during
assaying the binding of 1251-VT-1 to human GMVEC. The
anti-Gb3 MoAb inhibited the binding of 1251-VT-1 to TNFs-
stimulated GMVEC in a concentration dependent way, but,
probably because of the moderate affinity of the MoAb, no
complete inhibition was reached at the concentrations used
(18.3 0.3 and 27.7% 0.6 inhibition at 10 and 20% (vol/vol)
antibody solution, respectively).
To further characterize the nature of the receptor for VT-I
present on human GMVEC neutral glycolipid extracts were
prepared from both unstimulated and TNFa-stimulated human
GMVEC and thin layer chromatography of these extracts was
— performed. After incubation of these thin layer chromatograms
24 with 1251-VT-1 and extensive washing, the bound '251-VT-1 was
detected by exposure to a phosphor-imager. The radiolabeled
VT-l bound strongly to Gb3 and not to Gb4 when a standard
preparation of neutral glycolipids was tested (Fig. 7, lane C). In
unstimulated and TNFs-stimulated human GMVEC binding of
'251VT1 occurred predominantly to Gb3 (Fig. 7, lanes A, B).
This pattern was consistently found with different preparations of
human GMVEC obtained from two different donors. The in-
crease in 1251-VT-1 binding to the glycolipid extracts of TNFa-
stimulated human GMVEC indicates that the synthesis of VT-i
receptors is increased rather than that it only reflects a redistri-
bution of VT-i receptors from intracellular stores towards the
plasma membrane.
Effect of VT-I and VT-2 on protein synthesis
VTs may exert their cytotoxic effect by inhibiting the elongation
factor-i dependent binding of aminoacyl-tRNA to the ribosomcs
[28], a crucial step in the process of eukaryotic protein synthesis.
To investigate whether VT cytotoxicity in human GMVEC was
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Fig. 5. VT-I cytotoxicüy is related to the degree of confluence of human
GMVEC. Human GMVEC of one representative donor out of three were
grown to confluence, trypsinized and seeded 1:6 onto gelatin coated 24
wells plates. Forty-eight hours before the indicated time points after
trypsinization (as indicated on the x-axis) GMVEC were preincubated
with either control medium (same culture medium without addition; open
symbols) or TNFa (10 nglml; closed symbols) for 24 hours. Subsequently
the cells were washed and exposed to either control medium or VT-I (I
nmol/liter) for 24 hours, after which the number of viable adherent cells
was counted with a hemocytometer. GMVEC indicated by A were
categorized subconfluent (<50% confluent), by B "just reaching conflu-
ence" and by C "highly confluent" for respectively two, four and seven
days. A. Effect of VT-i on the viability of non-stimulated-(open symbols)
and TNFa-treated GMVEC (closed symbols). Symbols are: (V, V) control
cells; (0, S) VT-i treated cells. B. Effect of VT-i on the number of viable
adherent cells expressed as percentage of control (calculated by dividing
the number of viable cells after VT-I treatment by the number of viable
adherent cells exposed to control medium X 100%). Symbols are: (LI)
unstimulated GMVEC; (U) TNFa-prestimulated GMVEC. Similar re-
sults were obtained in two other experiments with two different donors.
based on inhibition of protein synthesis, newly synthesized pro-
teins were determined by assaying the incorporation of 35S-
methionine into total cellular proteins. In agreement with cell-
viability data, VT-i alone did not or only slightly affect protein
B (mol/ceII)x 10-17
Fig. 6. TNFa increases the specific binding of'251-l/T-I to human GMJ/EC.
A. Human GMVEC of one representative donor were grown to "just
reaching confluence" and pre-treated with either control medium (LI) or
TNFu (10 nglml; U) for 24 hours. Subsequently the cells were incubated
with increasing concentrations of '251-VT-l (0.25 to 32 nmol/liter) for
three hours at 4°C, after which specific binding of '251-VT-i to GMVEC
was calculated as indicated in the Methods section. B. Scatchard plot
analysis of 251-VT-i binding to human GMVEC preincubated with either
control medium (0) or TNFa (10 ng/ml; S) for 24 hours.
synthesis of highly confluent GMVEC over a 24-hour incubation
period, whereas it inhibited protein synthesis in subconfluent and
confluent cells (Fig. 8). When the highly confluent human GM-
VEC were preincubated with TNFs for 24 hours, the protein
synthesis rate was inhibited similarly to subconfluent cells. Table
I summarizes the results of protein synthesis inhibition by VT-i in
GMVEC differing in degree of confluence (N = 3). TNFa alone
did not decrease overall protein synthesis.
When the effect of VT-i and VT-2 on protein synthesis
inhibition on TNFa-stimulated GMVEC of two different donors
were compared, VT-i was slightly more potent in inhibiting
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Fig. 7. '251-VT-i binding to glycolipids extracted from human GMVEC.
Glycolipids were extracted from "highly confluent" human GMVEC,
separated by TLC and assayed for '251-VT-1 binding and visualized by a
phosphor imager. Lanes A and B. Glycolipid extracts of 20 cm2 human
GMVEC of one representative donor (lane A, control GMVEC; lane B,
TNFa-treated 10 nglml GMVEC). Lane C. Standard neutral glycolipids, 2
pg of each glycolipid. Lane D. Orcinol staining of standard neutral
glycosphingolipids (Gbl, galactosylceramide; Gb2, lactosylceramide; Gb3,
globotriaosylceramide; Gb4, globotetraosylceramide; Gb5, Forssman pen-
tasaccharide).
protein synthesis than VT-2, at all concentrations tested (Fig. 9).
The lowest dose to inhibit overall protein synthesis was 1 pmol/
liter for both VT-i and VT-2. No effect of VT-2 was observed on
the protein synthesis of non-stimulated highly confluent GMVEC.
Discussion
VT producing E. coli play an important role in the etiology of
the epidemic form of HUS. In this most common form of HUS in
young children, the hallmark of the pathogenetic mechanism is
endothelial cell damage, most predominantly displayed by the
glomerular capillaries. In this study we have described a modified
technique for the reproducible culture of large numbers of highly
purified human GMVEC that express a variety of endothelial-cell
specific antigens. Furthermore, we have demonstrated that sus-
ceptibility for the cytotoxic effect of VT-i of these highly purified
human GMVEC depended on the degree and duration of con-
fluence and additional preexposure to inflammatory mediators.
Pre-exposure to inflammatory mediators resulted in an increase in
specific binding sites for VT-I accompanied by a rise in cellular
amount of Gb3, known to be the functional receptor for VT-I.
Like other eukaryotic cells possessing the Gb3 receptor, cytotox-
icity was associated with protein synthesis inhibition.
The cytotoxic effect of VT on HUVEC and the presence of the
functional receptor Gb3 on HUVEC have been well described
[4—7]. Additional stimuli such as the inflammatory mediators
TNFcr and IL-la and LPS seemed to be crucial for VT to cause
cytotoxicity to HUVEC. Because VT appears to have a predilec-
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Fig. 8. The protein synthesis inhibitory effect of VT-i is related to the degree
of confluence of human GMVEC. The experimental design is comparable
to Figure 5. The incorporation of 35S-methionine in proteins by GMVEC
is shown at different degrees of confluence (A, B and C), either cultured
under basal conditions (open symbols) or pre-treated with TNFa (10
nglml; closed symbols) before exposing the cells to either control medium
(same culture medium without addition) or VT-i (1 nmol/liter). A. Effect
of VT-i on the incorporation of "S-methionine in proteins of non-
prestimulated GMVEC (V, 0) and TNFcs-pretreated GMVEC (V, •).
Symbols are: (V, 7) control cells; (S, 0) VT-I treated cells. B. Effect of
VT-i on the incorporation of 35S-methionine in proteins expressed as
percentage of control (35S-methionine incorporation in proteins of VT-l
treated cells by 35S-methionine incorporation in proteins of control cells ><
100%). Symbols are: (LI) unstimulated GMVEC; (U) TNFa-prestimu-
lated GMVEC. Similar results were obtained in two other experiments
with two different donors.
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tion for the glomerular microvascular endothelium in vivo, the
interaction of VTs with human glomerular microvascular endo-
thelial cells was studied in vitro. We investigated whether GM-
VEC display a higher basal susceptibility for VT than other
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Table 1. VT-i inhibitory effect on overall protein synthesis is related to the degree of confluence of human GMVEC
Incorporation of 35S-methionine in proteins % of control
Donor 1 Donor 2 Donor 3
Without WithWithout With Without With
TNFa TNFa TNFu TNFa TNFa TNFa
Subconfluent 54 35 5 2 51 30
Confluent 73 28 10 8 69 32
Highly confluent (2 days)
Highly confluent (4 days)
Highly confluent (7 days)
87
92
87
24
33
36
39
71
88
25
33
40
71
82
87
46
48
37
Experimental design as described in the legend of Figure 8. The data of three independent experiments are given. The incorporation of
35S-methionine in proteins is expressed as % of control [35S-methionine incorporation in proteins of VT-I (I nmol/liter) treated cells divided by
35S-methionine incorporation in proteins of control cells x 100%].
()
4—0
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Fig. 9. EJfrct of VT-I and VT-2 on protein synthesis by "highly confluent"
human GMVEC. Human GMVEC were grown to confluence and main-
tained confluent for five days. Subsequently the cells were pre-treated
without (open symbols) or with TNFa (10 nglml; closed symbols). After 24
hours of preincubation, the cells were washed and incubated with different
concentrations (0.1 pmollliter to I nmol/liter) of VT-I (0, •) and VT-2
(A, A) for 24 hours. Incorporation of 35S-methionine in proteins was
determined as described in the Methods section. Data are expressed as the
mean of two different experiments with two different donors (% of
control).
endothelial ceJis or need the local exposure to inflammatory
mediators to up-regulate Gb3 receptors and become suscep-
tible to the cytotoxic effect of VT, as seen in venous endothelial
cells.
Since Striker et al [101 and Green et al [12] described their
methods to isolate and purify human glomerular endothelial cells,
very few reports deal with glomerular endothelial cells in vitro,
reflecting difficulties in the process of isolating and purifying large
numbers of glomerular microvascular endothelial cells devoid of
contaminating mesangial- and epithelial cells. In this report we
have described an adapted procedure that is reproducible, rela-
tively simple to perform and yields high numbers of GMVEC. It
appeared to be crucial to avoid any contamination early in the
process of purification because a minute contamination of epithe-
hal or mesangial cells causes inhibition of GMVEC proliferation
and rapid overgrowth of the contaminating cells. By several
standard techniques the cultured cells have been characterized as
pure populations of glomerular microvascular endothelial cells.
The combined presence of the endothelial specific markers von
Willebrand factor, V,E cadherin and EN-4 antigen and PECAM-I
(which is only encountered on endothelial cells, leukocytes and
platelets), demonstrates the endothelial nature of our GMVEC.
Upon inflammatory activation the endothelial cell specific leuko-
cyte adhesion molecule E-selectin was also expressed. This agrees
well with observations in vivo [29—33] showing an induction of
E-selectin in glomeruli during inflammation. The presence of
fenestral structures suggests that one of the specific properties of
the glomerular endothelium is preserved in culture. Suboptimal
expression of fenestrae in these human GMVEC may be due to
the fact that they are cultured under static conditions. The need
for dynamic flow to induce the expression of fenestrae in cultured
glomerular endothelial cells was suggested by Ott, Olson and
Ballermann [341 who, in contrast to our findings, did not observe
fenestrae in bovine glomerular endothelial cells cultured under
static conditions, but were able to induce the expression of
fenestrae by shear forces.
Several papers have reported that HUVEC cultured under
basal conditions are resistant to the cytotoxic effect of VT-i [4—7].
When prestimulated with inflammatory mediators HUVEC be-
come susceptible to the cytotoxic effect of VT-I presumedly by an
up-regulation of the receptors for VT on the cell-surface [6].
Recently Obrig et al [13] have demonstrated that cell viability and
protein synthesis of unstimulated renal endothelial cells was
affected by VT with no alteration in sensitivity for VT when
pre-exposed to TNFn or LPS. Furthermore, Obrig et al described
high basal levels of VT receptor in renal endothelial cells reaching
concentrations approximately 50 times higher than in HUVEC.
These data suggest a higher relative sensitivity of renal endothelial
cells versus HUVEC and a possible explanation for localized
involvement of the kidney. In our study, cytotoxic and protein
synthesis inhibitory effects of VT were found only on GMVEC
that were subconfluent, just reaching confluence or pre-exposed
to the inflammatory mediator TNFa, but not in the highly
confluent GMVEC. Because Obrig et al have used cells one day
after seeding in wells, it is likely that they studied the effect of VT
on subconfluent or confluent renal endothelial cells.
Several papers have reported that subconfluent cells display a
significant higher binding capacity of radiolabeled VT-I and a
higher susceptibility to the cytotoxic effect of VT than confluent
cells [6, 35, 36]. Most probably this higher susceptibility of
subcorifluent and confluent cells is related to the cell-cycle
0.0001 0.001 0.01 0.1
VT concentration, nmol/Iiter
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dependent expression of Gb3 on the cell-surface compounded
with increased Gb3 turnover [36]. Our observation that the degree
of confluence of GMVEC affects susceptibility for VT corre-
sponds with these findings. Since the half life of endothelial cells
in the normal mature human body is approximately a hundred to
thousand days [37] and autoradiographic analysis in glomeruli of
rats demonstrated a constant rate of cell renewal of about 1%
[38], we believe that from pathophysiological point of view, data
on highly confluent cells are most appropriate in the study of the
pathogenetic mechanisms of HUS.
Infections with VT producing E. co/i most commonly involve
isolates producing either VT2 alone or VT-2 with YT1. The
structural genes of the two toxins share 58% overall nucleotide
and 56% projected amino acid sequence homologies [39]. The
toxins show similar physical properties such as toxin binding to
Gb3 and inhibition of protein synthesis by the same mechanism,
however, differences in biological activity have been observed. In
vitro studies comparing the cytotoxic effects of VT-i versus VT-2
on HUVEC [40], Vero [41], HeLa [41] and Daudi cells [42]
demonstrated reduced susceptibility to VT2. While performing
studies with VT1 and VT2 hybrid toxins [43] it was found that the
modulation in VT susceptibility is due to differences in the B
subunit. Furthermore, Head, Karmali and Lingwood's study pro-
vided evidence for reduced binding affinity of VT2 for Gb3 when
compared to VT1 [43]. This observation corresponds to our
finding concerning the slightly reduced cytotoxicity of VT2 in
GMVEC, but is in contrast with a recent study by Louise and
Obrig [40] suggesting an increased susceptibility of renal endo-
thelial cells for VT2. In vivo studies in mice [44] have demon-
strated enhanced lethality of Shiga-like toxin-2 when compared to
Shiga-like toxin-i (toxins closely related to VT-2 and VT-i,
respectively), suggesting that differences in properties other than
direct target cell lysis are responsible for the observed heightened
sensitivity of animals to VT-2.
Since in vitro data described in this report do not provide strong
evidence for an intrinsic enhanced basal susceptibility of GMVEC
to VT as a possible explanation for the preferential glomerular
microvascular endothelial cell damage observed in HUS patients,
the local availability of inflammatory mediators in glomeruli may
contribute to local susceptibility for the cytotoxic effect of VT. A
local role for inflammatory mediators was also suggested by Hard
et a! [45] reporting that Shiga-like toxin-i injection into transgenic
mice, bearing a chioramphenicol acetyltransferase (CAT) re-
porter gene coupled to a TNFa promoter, induced CAT activity
(reflecting stimulation of the TNF promoter) in the kidney but not
in other tissues. Monocytes and macrophages, known to produce
and release inflammatory mediators may be the source of locally
produced glomerular inflammatory mediators. Of interest are
recent in vitro studies of Tesh, Ramegowda and Samuel [46] and
Van Setten et a! [47], which describe the interaction of VT with
murine peritoneal macrophages and human monocytes, respec-
tively. Both cells upon VT binding do not display protein synthesis
inhibition but synthesize and release inflammatory mediators,
suggesting a key role for monocytes in the process of endothelial
cell damage in HUS. In vivo data supporting involvement of
inflammatory mediators in the pathogenesis of HUS are provided
by several papers demonstrating elevated concentrations of in-
flammatory mediators in plasma and urine among HUS patients
[48—51]. Other possible local sources of cytokine production
inside the glomerular capillaries such as mesangial [52, 53] and
epithelial [54] cells need further investigation. It remains to be
clarified for what reason inflammatory mediators are predomi-
nantly produced inside the glomerular capillaries.
Although our in vitro data strongly suggest that local availability
of inflammatory mediators is essential for VT to result in a
cytotoxic response, these data should be interpreted with some
reserve. Since mainly children are affected by infection with a VT
producing E. co/i, it remains to be investigated whether GMVEC
isolated from kidneys of juvenile origin display an increased
sensitivity towards VT cytotoxicity when compared to GMVEC
isolated from kidneys of adult origin. Of interest is the observation
of Lingwood [55] that FITC labeled VT binds to human renal
sections of infant < two years and not to the glomerulus of the
adult. It should be noted, however, that Lingwood for the most
part examined kidney sections of minimal lesion nephrotic syn-
drome patients, where locally released cytokines may induce the
Gb3 receptor [56—581 resulting in the observed enhanced VT
binding.
We conclude from this study with highly purified GMVEC,
showing glomerular microvascular endothelial cell specific fea-
tures, that VT cytotoxicity depends on the degree of confluence
and the additional pre-exposure to inflammatory mediators. The
latter are presumedly locally produced by monocytes and not only
up-regulate the receptor for VT, but also exert a variety of
pro-inflammatory and coagulatory effects on the endothelium,
resulting in a cascade of events of mutually influencing factors in
the end leading to glomerular capillary damage, as observed in
HUS patients.
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